BNET Industries
- Private
- CA
Dow Jones Description
Only 30 minutes from the heart of downtown Vancouver, the University of British Columbia holds an international reputation for excellence in advanced research and learning. The spectacular UBC campus is a 'must-see' for any visitor to the city -- where snow-capped mountains meet ocean, and breathtaking vistas greet you around every corner. The university boasts some of the city's best attractions & recreation facilities, including the Museum of Anthropology, the Chan Centre for the Performing Arts, the UBC Botanical Garden and Centre for Plant Research, and endless opportunities to explore forested trails in the adjoining 763-hectare Pacific Spirit Regional Park.
Contact Information
2329 West Mall
Vancouver, British Columbia V6T 1Z4
604.822.2211
NAICS Code Colleges, Universities, and Professional Schools: 611310
News & Analysis
Filter by
r&d and university of british columbia - All News and Analysis
MIV Therapeutics Highlights HAp Composite Coating Technologies at Leading Conference on Biomaterials; Better, Safer, More Biocompatible Stent Coating Technologies Presented at Recent International Society of Biomaterials Meeting
- 2006-05-08
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, provided detailed background in two scientific poster presentations on its advanced, proprietary coating achievements at the prestigious annual international meeting...
MIV Therapeutics to Highlight Latest HAp Advancements at Leading International Scientific Conference on Biomaterials; MIVT Accepted to Present Proprietary Biocompatible Stent Coating Technology at Society of Biomaterials Meeting
- 2006-01-31
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced today that it has been accepted to present some of its latest technology achievements at the annual international meeting...
MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in Development of New Generation Biomedical Technologies; Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
- 2006-01-04
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, has reported significant progress in a report outlining the achievement of numerous key strategic, corporate and technological objectives for 2005. "The past year has been a time of...
MIV Therapeutics Invited to Present Latest Data on Breakthrough Biofriendly Coating at Leading Medical Device Conference; Invitation Recognizes Potential of MIVT Proprietary Coating to Improve Stent and Drug-Delivery Effectiveness and Safety
- 2005-11-02
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, have been invited to present their latest achievements in research and development of novel coatings designed to significantly...
MIV Therapeutics Names Arc Rajtar to Post of Chief Technology Officer as Company Accelerates R&D Programs; Major Promotion Expands Oversight for Development of Proprietary HAp Biocompatible Drug-Eluting Medical Device Coatings
- 2005-09-23
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced today that it has promoted veteran biomedical industry engineer Arc Rajtar, MSc. Eng., to the position of Chief Technology Officer, in...
MIVT LICENSES BIOCOMPATIBLE MEDICAL DEVICE COATINGS.
- 2005-07-01
MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has exercised the option provided in the collaborative research agreement with The University of British Columbia UBC to license two new technologies for advanced biocompatible coatings for cardiovascular stents and...
MIV Therapeutics Exercises Option to License Additional Proprietary Technologies for Biocompatible Drug-Eluting Coatings; New Licenses from U. of British Columbia will Strengthen Intellectual Property Portfolio in Novel Coatings for Medical Devices
- 2005-06-08
VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced it has exercised the option provided in its Collaborative Research Agreement with the University of British Columbia UBC to license two additional technologies for advanced biocompatible and drug-eluting coatings for...
MIV Therapeutics Expands Intellectual Property Portfolio with New Technologies for Next-Generation Biocompatible Medical Device Coatings
- 2005-05-20
VANCOUVER, British Columbia -- Proprietary Technologies, Licensed from Univ. of British Columbia, Include New Coatings for Advanced Drug-Eluting Applications MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced that it has exercised the Option provided in the Collaborative Research Agreement with The...
MIV Therapeutics Builds Strength of Drug-Delivery Technologies Program with Appointment Of Dr. Dean-Mo Lui as Chief Scientist
- 2005-03-31
VANCOUVER, British Columbia -- Industry-Renowned Scientist Brings Extensive Leadership in Development of Advanced Bioceramics and Biomedical Industry MIV Therapeutics, Inc. (OTCBB: MIVT) a developer of next-generation biocompatible stent coatings and drug delivery technologies, today announced the addition of Dr. Dean-Mo Liu, Ph.D., to the post of Chief Scientist, Drug...
MIV Therapeutics Receives Government Grant to Expedite Development of Proprietary HAp Stent Coating for Drug Delivery Technologies
- 2005-03-22
VANCOUVER, B.C. -- MIV Therapeutics Inc. (MIVT: OTCBB) announced today that its wholly-owned subsidiary, MIVI Technologies Inc., that is involved in the research and development of multilayer coating technologies with drug eluting capability for cardiovascular stents and other implantable devices, has received a Government grant for the research program titled...
- 1
- 2
Glass Door
| Company | Employer Rating |
| Alcoa |  |
| CBS Corp |  |
| Johnson & Johnson | |
| Costco Wholesale |  |
|
IndustryTop Rated
